Industry
Dermata Therapeutics
Total Trials
6
Recruiting
0
Active
0
Completed
5
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
Failure Rate
0.0%
0 terminated/withdrawn out of 6 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Phase 2
5(83.3%)
Phase 3
1(16.7%)
6Total
Phase 2(5)
Phase 3(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (6)
Showing 6 of 6 trials
NCT06090721Phase 3Completed
DMT310-009 Topical in the Treatment of Acne Vulgaris
Role: lead
NCT05108025Phase 2Unknown
DMT310-005 Topical in the Treatment of Acne Rosacea
Role: lead
NCT03536637Phase 2Completed
DMT310-001 Topical in the Treatment of Acne Vulgaris
Role: lead
NCT04106778Phase 2Completed
DMT310-003 Topical in the Treatment of Acne Vulgaris
Role: lead
NCT02949960Phase 2Completed
DMT210 Topical Gel in the Treatment of Atopic Dermatitis
Role: lead
NCT03003104Phase 2Completed
DMT210 Topical Gel in the Treatment of Acne Rosacea
Role: lead
All 6 trials loaded